ESMO 2018 Congress
The ESMO 2018 Congress took place on October 19th through the 23rd, in Munich, Germany, under the tagline “Securing access to optimal cancer care.”
The congress welcomed oncology professionals, including researchers, clinicians, cancer nurses, industry partners, patient advocates, and members of the press to have important discussions on securing better patient outcomes through access to high-quality care.
Oncology Learning Network provided coverage of a variety of topics presented at the ESMO 2018 Congress, listed below.
---
IMpassion130: Immunotherapy Improves Survival in Patients With Treatment-Naive Metastatic TNBC
Patients with metastatic triple negative breast cancer who have PD-L1 positive tumors had improved survival when treated with atezolizumab in combination with nab-paclitaxel.
Novel PI3K Inhibitor Improves Survival for Patients with PIK3CA-Mutated Breast Cancer
The alpha-specific PI3K inhibitor alpelisib significantly improved progression-free survival in patients with hormone receptor positive HER2-negative advanced breast cancer.
Local Radiotherapy Improves Survival in Patients With Oligometastatic Prostate Cancer
Radiotherapy to the prostate can improve survival in patients with newly-diagnosed metastatic prostate cancer who have a low metastatic disease burden.
A combination of the immune checkpoint blocker, avelumab, plus the TKI, axitinib, significantly improves PFS in previously untreated patients with advanced RCC.
